Life Science Investing Nektar Presents New Data from REZOLVE-AD Phase 2b Study for Rezpegaldesleukin in Late-Breaker Oral Presentation at EADV 2025
Life Science Investing Nektar Announces REZOLVE-AD Phase 2b Results for Rezpegaldesleukin Selected for Late-Breaker Oral Presentation at EADV 2025
Blackrock Announces Arrangements to Address Mailing of Meeting Materials Resulting from the Canada Post Strike